Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei

Joal D. Beane, Gregory C. Wilson, Jeffrey M. Sutton, Yongli Shuai, Lekshmi Ramalingam, Heather L. Jones, James F. Pingpank, Matthew P. Holtzman, Amer J. Zureikat, Steven A. Ahrendt, Herbert J. Zeh, David L. Bartlett, Haroon A. Choudry

Research output: Contribution to journalArticle

3 Scopus citations

Abstract

Background: The aim of this study was to identify factors associated with pleuropulmonary disease recurrence following cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (CRS/HIPEC) for appendiceal pseudomyxoma peritonei (PMP) and to evaluate the oncologic impact of pleuropulmonary disease recurrence compared with isolated peritoneal recurrence. Methods: From a prospective database, we identified patients who developed pleuropulmonary recurrence, isolated peritoneal recurrence, or no recurrence following CRS/HIPEC for appendiceal PMP. Clinicopathologic, perioperative, and oncologic data associated with the index CRS/HIPEC procedure were reviewed. The Kaplan–Meier method was used to estimate survival. Multivariate analyses identified associations with recurrence and survival. Results: Of 382 patients undergoing CRS/HIPEC, 61 (16%) developed pleuropulmonary recurrence. Patients who developed a pleuropulmonary recurrence were more likely to have high-grade (American Joint Committee on Cancer [AJCC] grade 2/3) tumors (74% vs. 56%, p = 0.02) and increased operative blood loss (1651 vs. 1201 ml, p = 0.05) and were more likely to have undergone diaphragm stripping/resection (79% vs. 48%, p < 0.01) compared with patients with an abdominal recurrence. In a multivariate analysis, pleuropulmonary recurrence after CRS/HIPEC was associated with diaphragm stripping/resection, incomplete cytoreduction, and higher AJCC tumor grade. There was a trend towards reduced survival in patients with pleuropulmonary recurrence compared with patients with isolated peritoneal recurrence (median overall survival 45 vs. 53 months, p = 0.87). Conclusion: Pleuropulmonary recurrence of appendiceal PMP following CRS/HIPEC is common and may negatively impact survival. Formal protocols for surveillance and therapeutic intervention need to be studied and implemented to improve oncologic outcomes.

Original languageEnglish (US)
Pages (from-to)1429-1436
Number of pages8
JournalAnnals of Surgical Oncology
Volume26
Issue number5
DOIs
StatePublished - May 15 2019

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei'. Together they form a unique fingerprint.

  • Cite this

    Beane, J. D., Wilson, G. C., Sutton, J. M., Shuai, Y., Ramalingam, L., Jones, H. L., Pingpank, J. F., Holtzman, M. P., Zureikat, A. J., Ahrendt, S. A., Zeh, H. J., Bartlett, D. L., & Choudry, H. A. (2019). Pleuropulmonary Recurrence Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Appendiceal Pseudomyxoma Peritonei. Annals of Surgical Oncology, 26(5), 1429-1436. https://doi.org/10.1245/s10434-018-07091-z